Turn Therapeutics (TTRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $8.00 price target on the stock.
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences